P21-Associated ncRNA DNA Damage-Activated Expression in Bladder Cancer. 2019

Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Úvod: Dlouhé nekódující ribonukleové kyseliny (long non-coding ribonucleic acids - lncRNA) jsou v poslední době vzhledem ke své úloze v procesu karcinogeneze předmětem zkoumání vědců zabývajících se nádory. Tyto transkripty regulují kritické kroky v normálních buněčných procesech, takže dysregulace jejich exprese se účastní patogeneze karcinomů. Z důvodu své blízkosti k lokusu CDKN1A má ncRNA spojená s P21 aktivovaná poškozením DNA (P21-associated ncRNA DNA damage activated - PANDA) v tomto ohledu zvláštní pozici. Podílí se na regulaci reakce na poškození DNA, stárnutí buněk a proliferace. Materiály a metody: V této studii jsme metodou kvantitativní polymerázové řetězové reakce hodnotili expresi této lncRNA ve tkáních karcinomu močového měchýře, sousedních nerakovinných tkání (adjacent non-cancerous tissues - ANCT) a v normálních vzorcích močového měchýře. Výsledky: Nebyl detekován žádný významný rozdíl v expresi PANDA, a to ani mezi nádorovými tkáněmi a ANCT (poměr exprese = 1,75; p = 0,11) nebo mezi nádorovými tkáněmi a normálními tkáněmi (poměr exprese = 2,72; p = 0,57). Úroveň exprese této lncRNA nebyla spojena s žádnými demografickými ani klinickými údaji o pacientech, jako je grade nádoru nebo recidiva, ani s rizikovými faktory souvisejícími s rakovinou, mezi něž patří např. kouření cigaret nebo závislost na opiu. Závěr: Tato studie tedy naznačuje, že PANDA není zapojena do patogeneze karcinomu močového měchýře. Hodnocení exprese jiných lncRNA by mohlo pomoci při identifikaci biomarkerů pro tyto karcinomy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
March 1994, Journal of occupational medicine. : official publication of the Industrial Medical Association,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
June 2006, Nature reviews. Cancer,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
May 2018, DNA repair,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
July 2018, Oncogene,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
January 2013, PloS one,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
July 2017, Oncology letters,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
December 2015, Chemico-biological interactions,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
October 2019, Cancer prevention research (Philadelphia, Pa.),
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
January 2002, Urologic oncology,
Feraydoon Abdolmaleki, and Soudeh Ghafouri-Fard, and Mohammad Taheri, and Davood Mir Omrani
December 2003, Cancer metastasis reviews,
Copied contents to your clipboard!